What is the market price of selpercatinib?

Selpercatinib has a significant effect on RET-mutated cancers, especially in the treatment of non-small cell lung cancer. It stops tumor development by interfering with the signaling of cancer cells; Patients with a variety of cancer types benefit from the clinical application of drugs.

What is the market price of Selpercatinib?

The packaging specification of Selpercatinib produced by Bangladesh Everest Pharmaceutical is 40mg*30 capsules per box, and the market price is about 2,200 yuan; The Lucius version of Selpercatinib is sold in large packages of 40mg and 120 capsules, and the price is relatively more economical, about 3,375 yuan per box. The above prices are for reference only.

When patients purchase drugs, they should choose formal channels to ensure the quality of drugs. Fully communicate with doctors and pharmacists before purchase, understand the price of drugs and purchase channels, and help arrange treatment costs reasonably; Avoid purchasing medicines through informal channels.

What are the precautions for the use of Selpercatinib?

Patients should be aware of the precautions for the use of the drug before using it for treatment.

1. Hyperphosphatemia and soft tissue mineralization

The use of Selpercatinib may lead to hyperphosphatemia, a pathological condition triggered by abnormally elevated phosphate levels. Hyperphosphatemia may in turn contribute to mineralization of soft tissues, manifested by skin calcification, calcinosis, and nonuremic calcifications. These side effects are part of the pharmacodynamic effects of Selpercatinib.

2. Bleeding events

Serpatinib should be permanently discontinued in patients with severe or life-threatening bleeding events.

Drug Interactions of Serpatinib?

Understanding drug interactions can help patients reduce the risk of unnecessary drug interactions and avoid associated adverse effects.

1. Strong and moderate CYP3A inducers

Concomitant use of Selpercatinib and strong or moderate CYP3A inducers results in a decrease in plasma concentrations of Selpercatinib, which may affect efficacy, and this combined effect should be avoided.

2. Strong and moderate CYP3A inhibitors

The use of strong or moderate CYP3A inhibitors increases plasma concentrations of Selpercatinib and increases the risk and severity of adverse effects. Concomitant use with these inhibitors should be avoided. If simultaneous use is necessary, it is recommended to reduce the dose of Selpercatinib.

[Warm tips] Tell your doctor about all medications you're taking, including prescription, over-the-counter and supplements, to avoid potential drug interactions.